目的 分析2023年安徽省从1例非急性弛缓性麻痹(AFP)病例中分离到的2株I型疫苗衍生脊髓灰质炎病毒(VDPV)的基因型别及特征,探讨其对安徽省维持无脊髓灰质炎状态的影响。方法 从2023年安徽省报告的1例非AFP病例双份粪便标本中分离脊髓灰质炎病毒(PV),用实时荧光定量RT-PCR方法对其进行型内鉴定,通过中和实验获得单型毒株,提取病毒RNA,进行RT-PCR扩增,对VP1区进行核苷酸序列测定和分析。结果 从1例非AFP病例粪便标本中分离出2株I+III混合型PV,其中I型(2023MYKJH 01-1和2023MYKJH 01-2)分别有13和12个核苷酸变异,变异率分别为1.4%和1.3%,鉴定为I型VDPV,与近年来我国其他省份监测到的I型VDPV处于不同分支,III型为疫苗相似株。后续采集的粪便标本未分离到I型VDPV。结论 2023年安徽省检出两株Ⅰ型VDPV的非AFP病例未持续排毒,发生I型VDPV循环的风险较低。
Abstract
Objective To analyze the genotypes and characteristics of two vaccine-derived poliovirus (VDPV) strains isolated from a non-acute flaccid paralysis (non-AFP) case in Anhui Province in 2023,and to explore the influence of this case on maintaining polio-free status in Anhui province. Methods Poliovirus (PV) was isolated from two samples of a non-AFP case in Anhui Province in 2023.The PV was identified by real time fluorescent quantitative RT-PCR.The single type strain was obtained by neutralization experiment,the viral RNA was extracted and amplified by RT-PCR,and the nucleotide sequence of VP1 region was determined and analyzed. Results Two mixed type I+III PV strains were isolated from the double fecal samples of the non-AFP case.Type I (2023MYKJH 01-1 and 2023MYKJH 01-2) had 13 and 12 nucleotide variants,with variation rates of 1.4% and 1.3%,respectively,they were identified as type I VDPV and in a different branch from the type I VDPV detected in other province in China in recent years.Type III were vaccine-like strains.Type I VDPV was not isolated from subsequent stool samples. Conclusion One non-AFP case of two type I VDPV strains detected in Anhui Province in 2023 did not undergo continuous detoxification,resulting in a lower risk of developing type I VDPV circulation.
关键词
疫苗衍生脊髓灰质炎病毒 /
型内鉴定 /
序列分析
Key words
Vaccine-derived polioviruses /
Intratypic differentiation /
Sequence analysis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Centers for Disease Control and Prevention (CDC).Progress toward interruption of wild poliovirus transmission-worldwide,January 2005-March 2006[J].MMWR Morb Mortal Wkly Rep,2006,55(16):458-462.
[2] 陈晓琴,赵月萍,丁一新,等.安徽省1991—1995年脊髓灰质炎实验室监测结果分析[J].安徽预防医学杂志,1996,2(4):1-4.
[3] 赵月萍,沈永刚,陈晓琴,等.安徽省1989—2000年脊髓灰质炎实验室监测分析[J].安徽预防医学杂志,2001,7(4):244-247.
[4] WHO.Polio-now[EB/OL].[2023-08-01](2023-01-03).https://polioeradication.org/polio-today/polio-now/.
[5] Ciapponi A,Bardach A,Rey Ares L,et al.Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis[J].Cochrane Database Syst Rev,2019,12(12):CD011260.
[6] 温宁,苏琪茹,安志杰,等.中国脊髓灰质炎疫苗免疫策略的思考及建议[J].中国疫苗和免疫,2018,24(3):349-353.
[7] Zhao K,Jorba J,Shaw J,et al.Are circulating type 2 vaccine-derived polioviruses (VDPVs) genetically distinguishable from immunodeficiency-associated VDPVs ？[J].Comput Struct Biotechnol J,2017,15:456-462.
[8] Circulating vaccine-derived poliovirus.Polio Now[EB/OL].[2023-08-08](2023-01-03).https://polioeradication.org/polio-today/polio-now/.
[9] 陈美钟,张薇,黄淑芬,等.广东省1例原发性免疫缺陷患者排出的Ⅱ型疫苗衍生脊髓灰质炎病毒分子病毒学特征[J].中国疫苗和免疫,2022,28(3):263-267.
[10] Kew OM,Sutter RW,de Gourville EM,et al.Vaccine-derived polioviruses and the endgame strategy for global polio eradication [J].Annu Rev Microbiol,2005,59:587-635.
[11] 张勇,严冬梅,赵月萍,等.1例疫苗相关麻痹型脊髓灰质炎的免疫缺陷患者持续排出疫苗衍生脊髓灰质炎病毒[J].中国计划免疫,2006.12(3):161-167.
[12] 严冬梅,祝双利,张勇,等.山西省2007年I型疫苗衍生脊髓灰质炎病毒的鉴定和基因特性分析[J].中国疫苗和免疫,2009,15(2):131-134.
[13] Kew O,Morris-Glasgow V,Landaverde M,et al.Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus[J].Science,2002,296(5566):356-359.
[14] 唐海淑,李晓嫘,凯塞尔·吾斯曼,等.2018年新疆维吾尔自治区外环境污水中分离到1株II型疫苗衍生脊髓灰质炎病毒[J].中国疫苗和免疫,2019,25(4):368-372.
[15] Jorba J,Campagnoli R,De L,et al.Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range[J].J Virol,2008,82(9):4429-4440.
PDF(820 KB)
